Sign Up to like & get
recommendations!
0
Published in 2018 at "European Respiratory Journal"
DOI: 10.1183/13993003.01562-2018
Abstract: Background Anlotinib has been demonstrated in clinical trials to be effective in prolonging the progression-free survival (PFS) and overall survival (OS) of refractory advanced nonsmall cell lung cancer (NSCLC) patients. However, the underlying molecular mechanisms…
read more here.
Keywords:
anti angiogenesis;
nsclc patients;
anlotinib;
nonsmall cell ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Current pharmaceutical design"
DOI: 10.2174/1381612827666211006145141
Abstract: BACKGROUND Anlotinib is a new tyrosine kinase inhibitor developed in China that targets the receptors for vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, and stem cell factor. Therefore, anlotinib inhibits tumor angiogenesis,…
read more here.
Keywords:
growth factor;
induced hypertension;
anlotinib induced;
hypertension ... See more keywords